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Abstract
The first clinical descriptions of autosomal dominant polycystic kidney disease
(ADPKD) go back at least 500 years to the late 16  century. Advances in
understanding disease presentation and pathophysiology have mirrored the
progress of clinical medicine in anatomy, pathology, physiology, cell biology,
and genetics. The identification of and 2, the major genes mutatedPKD1 PKD
in ADPKD, has stimulated major advances, which in turn have led to the first
approved drug for this disorder and a fresh reassessment of patient
management in the 21  century. In this commentary, we consider how clinical
management is likely to change in the coming decade.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the 
most common inherited renal disease worldwide and the fourth 
most common cause of end-stage renal disease (ESRD)1. It is a 
significant economic health burden to societies, and annual costs 
of providing renal replacement therapy (RRT) within the European 
Union (EU) are estimated at 1.2 billion euros. The median age of 
ESRD for patients with ADPKD within the EU is 58 years and 
has shifted only slightly over the past two decades (1991–2010) 
with the acceptance of older patients onto RRT programmes2. The 
management of ADPKD, long considered an untreatable disease, is 
undergoing a major paradigm shift with regulatory approval of the 
first effective drug for delaying disease progression. In this review, 
we consider some of the major recent advances that have led to this 
shift in clinical management.
Prevalence, natural history, and clinical presentation
Estimates of the prevalence of ADPKD vary widely depending 
on the population studied, methodology used, and local screen-
ing policy1. Within the EU, ADPKD is now considered to fulfil the 
definition of a rare disease (less than 1 in 2,000 affected) and 
has implications for health policy and funding3. This issue is 
still debated (asymptomatic cases may be undiagnosed without 
comprehensive screening of at-risk family members), but the 
definition probably applies to symptomatic cases.
The diagnostic uncertainty, especially early in disease, reflects the 
natural history of the condition with a long phase of stable renal 
function (glomerular filtration rate, or GFR) followed by a steep 
linear decline late in the course of disease (Figure 1). The latent 
phase of disease, especially in the early years, masks subtle changes 
in kidney physiology and the often silent but progressive expansion 
in kidney size. Studies in children with ADPKD reveal glomeru-
lar hyperfiltration, microalbuminuria, loss of urinary concentra-
tion, and loss of the normal diurnal blood pressure rhythm as early 
subclinical manifestations4–7.
Depending on the health system, patients may opt to undergo 
cascade screening or may present with typical symptoms (uri-
nary tract infection, macroscopic haematuria, renal pain, or 
kidney stones) at different ages8. A significant proportion of at-risk 
individuals remain asymptomatic, being diagnosed incidentally 
or through the detection of hypertension or reduced GFR. Often 
ignored are psychological symptoms reflective of concern and 
loss of hope about the future (risk of inheriting the disease, uncer-
tainty about the timing, and options for delaying ESRD) as well as 
inter-personal issues (guilt about transmitting the condition to the 
next generation) which impact individual quality of life9.
Diagnostic modalities and genetic testing
Mutations in two genes, PKD1 and PKD2, have been found in over 
90% of patients with ADPKD, and no mutations have been detected 
in 8% to 10%. Evidence of a third gene, GANAB, was recently 
reported, although this accounts for only a small number of these 
PKD1 and PKD2 mutation-negative patients10. In these patients, the 
renal phenotype was mild and the extent of liver disease was highly 
variable. It seems likely that incorrect ascertainment11, mutations 
in promoter regions, or mutations in other unidentified genes could 
account for the rest.
Figure 1. The natural history of autosomal dominant polycystic 
kidney disease as depicted by renal function decline as 
well as the onset of physical and psychological symptoms. 
Reductions in total nephron mass are masked by compensatory 
changes in glomerular filtration rate (GFR) such that total GFR 
remains apparently normal for many years until compensation fails. 
Subclinical physiological changes are detectable from the earliest 
stages of disease (for example, in children), whereas clinical 
symptoms usually occur later. The psychological burden of having 
the diagnosis made is generally underestimated.
In large published series, the percentage of patients with PKD2 
mutations ranges from 10.5% to 22%12–15. This is very likely to 
reflect criteria for patient referral and selection, including their stage 
of kidney function. In recent data obtained from the PKD muta-
tion database (accessed 22 April 2016), 81% and 19% of curated 
patients had PKD1 and PKD2 mutations, respectively (Figure 2). 
Although all mutation types have been reported for both genes, it is 
striking that only 10% of PKD2 mutations were missense (com-
pared with 27% of PKD1). This could reflect the under-diagnosis 
of milder asymptomatic cases of PKD2 present in the general 
population.
Although the two ADPKD proteins have been shown to func-
tion as a heterodimeric complex, patients with PKD2 have milder 
disease and the median age of ESRD is between 20 and 25 years 
later than that for PKD1 for reasons that are still unclear16. This has 
contributed to diagnostic uncertainty, especially when radiological 
methods were used in younger patients (under 40 years). Newer 
ultrasound diagnostic criteria have been published which extend 
the previous criteria (Ravine et al.) restricted to those at 50% risk 
of inheriting PKD1 to those with PKD2 or without a positive fam-
ily history17. In addition, magnetic resonance imaging criteria 
applying to those with a negative or uncertain family history have 
been published18.
Where diagnostic uncertainty remains, mutation analysis for 
both genes is becoming routine despite the technical challenge of 
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Figure 2. Frequency and type of PKD1 and PKD2 mutations from the PKD mutation database. All mutation types have been reported for 
both genes. The relative infrequency of missense mutations and in-frame insertions or deletions for PKD2 could reflect the under-diagnosis 
of these patients present in the general population. The PKD mutation database is available at http://pkdb.mayo.edu/index.html (accessed 
22 April 2016).
analysing PKD1. Within the National Health Service (UK), testing 
is currently restricted to several patient groups for whom diagnostic 
certainty is clinically helpful. These include the need to exclude 
risk in potential living related kidney donors19, those with atypical 
disease or a negative family history, rare cases of very early onset 
disease (less than 1%)20 in which the recurrence rate is high for 
subsequent pregnancies, and in pre-natal or pre-implantation diag-
nosis. Traditional Sanger sequencing is being rapidly replaced by 
newer approaches using next-generation sequencing (NGS) tech-
niques. The first uses long-range polymerase chain reaction to 
selectively amplify the PKD1 transcript (and not those arising from 
the six PKD1 homologous genes, or HGs)21. The second has used a 
bioinformatics approach to distinguish sequence reads from 
genomic DNA unique to PKD1 from the HG loci22. As the cost 
of testing falls, it is likely that these NGS methods will transform 
the use of testing for both diagnostic and prognostic (see below) 
purposes. A list of laboratories world-wide offering mutation 
analysis for PKD1 and PKD2 can be found on the GeneTests web-
site (https://www.genetests.org/disorders/?disid=78527&ps=chld 
and https://www.genetests.org/disorders/?disid=78530&ps=chld).
Prognostic prediction and scores
The known individual phenotypic variability of disease and recent 
availability of a potential effective treatment have stimulated efforts 
to derive an accurate prognostic score that could be clinically 
useful. Two main prognostic models have been proposed. The 
Mayo Classification relies on age-banded height-adjusted total 
kidney volume (TKV)23, whereas the PROPKD score24 relies on 
genotype and the age of onset of clinical symptoms. Although 
the two scores have not been directly compared, they have their 
relative merits. The Mayo Classification distinguishes two classes 
of disease (1 typical and 2 atypical) on the basis of a retrospec-
tive analysis of a historical cohort of 590 patients seen at a single 
centre23. Class 1 could be further subdivided into five subclasses 
(A to E) on the basis of the measured historical rate of kidney growth 
(on serial magnetic resonance or computed tomography), which in 
turn correlated with the rate of estimated GFR (eGFR) decline in 
the test population. This simple classification was then shown to 
have predictive value in both internal (n = 162) and external (n = 
173, Consortium for Radiologic Imaging Study of PKD or CRISP) 
validation cohorts. Patients in class 1C–E were shown to have more 
rapidly progressive disease (>3 ml/min per year) than those with 
class 1A and B. The PROPKD score combined genotype, gender, 
and an age cut-off (< or >35 years) of onset of urinary symptoms 
or hypertension on the basis of a cross-sectional study of the Genkyst 
cohort, a population of 1,341 patients from Brittany24. On the 
basis of these criteria, the authors propose three groups of patients 
with low, intermediate, or high risk for progression to ESRD.
The advantage of the Mayo Classification is the ability to predict 
prognosis on the basis of a single TKV measurement. The authors 
also propose that TKV can account for individual differences related 
to genotype as well as non-allelic factors. This study was based 
on a population with preserved initial eGFR (median 75 ml/min per 
Page 4 of 9
F1000Research 2016, 5(F1000 Faculty Rev):2029 Last updated: 18 AUG 2016
1.73 m2) with a low incidence of ESRD (22%) and has the advan-
tage of studying patients at earlier stages of disease23. However, 
whereas the majority of patients (>85%) remained within the same 
subclass over time, a number of 1A–D patients (13.4% of 284) 
moved to the higher subclass over time whereas a similar number 
of 1B–E patients (13.1% of 282) moved to the lower subclass. The 
Genkyst cohort was enriched for patients who had reached ESRD 
(44.6% versus 22.3%) and was therefore older (54.7 versus 44 years 
of age) than the Mayo cohort24. Clinical scoring relied on a cut-
off of 35 years and therefore could not be applied consistently to 
younger patients without symptoms. It should be noted that although 
these scores can distinguish groups or classes within populations, 
there was significant variability within the same groups, limit-
ing precision for predicting individual prognosis15,23,24. Further 
refinement will be necessary to improve precision for the 
individual patient and probably will involve a combination of 
imaging, genetic, and clinical scoring1.
For imaging, issues of access, speed, and accuracy of analysis25,26 
as well as harmonisation of accepted standards at a national and 
international level will be needed. For genotype-based scoring, 
further refinement of the ‘strength’ of non-truncating mutations 
through bioinformatics15, family studies14, or experimental 
approaches27,28 could increase its predictive value. The added 
value of other novel biomarkers29–31 to improve the performance of 
both models will need to be formally tested.
Treatment options
The approval of tolvaptan by regulatory authorities in Europe and 
around the world (though not in the USA) for use to slow renal 
disease progression in ADPKD patients with preserved renal 
function and evidence of rapidly progressive disease marks a major 
step-change in the management of this condition. This decision fol-
lows the pivotal TEMPO3/4 trial showing significant benefits of 
treatment on the rate of change in TKV as well as the decline in 
eGFR32. However, the eligibility criteria for prescribing tolvaptan 
do vary between countries where approval has been granted 
(Table 1). The European Renal Association-European Dialysis and 
Transplant Association (ERA-EDTA) and the Renal Association 
have issued more detailed guidance as to what constitutes ‘evidence 
of rapid disease progression’ so that treatment is offered to patients 
who are at the highest risk of developing ESRD and therefore 
potentially the ones to benefit33. The decision pathway published 
by the Renal Association for the UK is shown in Figure 3 (http://
www.renal.org/guidelines/commentary-on-nice-guidelines#sthash.
OrPl3wDl.yCJcc9PF.dpbs). It is clear that the risks and benefits 
of taking tolvaptan will need to be carefully considered, especially 
the need for monthly monitoring of liver function tests and the 
profound aquaretic side-effects requiring high water intake on a 
daily basis.
A number of other drugs, including somatostatin analogues and 
tyrosine kinase inhibitors, are currently being tested in clinical 
trials1,34. Potentially, these could be used in combination with 
tolvaptan if combined efficacy can be shown clinically as in 
preclinical models. Many other dietary and therapeutic agents have 
been shown to have efficacy in preclinical models, although the 
salutary experience with mammalian target of rapamycin (mTOR) 
inhibitors has demonstrated the potential divergence between 
preclinical results and clinical trials35,36. The experience gained 
from published trials will improve patient selection, harmonise 
outcome measures, and likely improve future trial design1.
Table 1. Eligibility criteria for the approved use of tolvaptan according to country or region.
Country
Chronic 
kidney disease 
stage
Disease activity Regulatory body Approval date Guidance (if any)
Japan 1–4
TKV >750 ml 
ΔTKV >5% per 
annum
Pharmaceuticals and 
Medical Devices Agency March 2014
Canada Not specified Not specified Health Canada February 2015
Europe 1–3
Evidence of 
rapid disease 
progression
European Medicines 
Agency May 2015
European Renal 
Association-European 
Dialysis and Transplant 
Association
England, Wales, 
and Northern 
Ireland
2–3
Evidence of 
rapid disease 
progression
National Institute for Health 
and Clinical Excellence 
(NICE)
October 2015 Renal Association
South Korea 1–3
Evidence of 
rapid disease 
progression
Ministry of Food and Drug 
Safety/Health Insurance 
Review and Assessment 
Service
December 2015
Scotland 1–3
Evidence of 
rapid disease 
progression
Scottish Medicines 
Consortium January 2016 Renal Association
TKV, total kidney volume.
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Figure 3. Recommended decision pathway for UK patients considered for treatment with tolvaptan according to Renal Association 
guidance based on the NICE decision. NICE has recommended that autosomal dominant polycystic kidney disease patients in England 
with chronic kidney disease stages 2 or 3 and evidence of rapidly progressive disease are eligible for treatment. This decision differs from 
that made by the Scottish Medicines Consortium and the European Medicines Agency in excluding patients with chronic kidney disease 
stage 1. Evidence of rapid disease progression has been defined as a significant decline in estimated glomerular filtration rate or increase in 
total kidney volume or both. In the absence of such evidence, risk prediction algorithms based on total kidney volume (Mayo Classification) 
or genotype (PROPKD) are the best predictors of prognosis. NICE, National Institute for Health and Clinical Excellence.
A new pathway for managing ADPKD in clinical 
practice
The rapid progress from gene discovery and understanding of 
pathophysiology to the first effective treatment for slowing disease 
progression is changing the management paradigm for ADPKD and 
stimulating the development of a new patient pathway (Figure 4)1. 
Ideally, this should take the form of a multidisciplinary approach 
beyond measuring renal function and blood pressure. It should con-
sider the management of extra-renal complications (often neglected), 
which often can give rise to refractory and worrying symptoms37–39. 
Family members who are at risk of inheriting the disease should 
be counselled and offered screening. Psychological and inter-per-
sonal issues, including ‘genetic guilt’ (of passing the disease on), 
are often silent and need to be explored at an early stage9. Patients 
would benefit from joining local support groups or being part of 
a patient organisation. Accurate information (clinical, genetic, die-
tary, or therapeutic) is critical and may be best delivered through 
nursing or medical staff with expert knowledge. All patients should 
be offered initial evaluation in specialist PKD clinics with follow-
up in secondary or primary care as appropriate to the individual. 
Confirmed ADPKD diagnosis
CKD2–3* (eGFR 30–89)
Age ≥18 yrs
*CKD1–3 (eGFR >30) 
in Scotland only 
∆eGFR >2.5 ml/min/pa
(5 points over 5 years)
OR
∆eGFR >5 ml/min over 12 mths
∆TKV >5% (MR or CT)
3 measurements over 2–3 yrs
Eligible for treatment
Evidence Declining GFR Increasing size
No evidence Risk prediction
US-MKL
Single MR/CT No MR/CT
FH ESRD
<55 yrs
PROPKD 
score
>16.5 cm <16.5 cmHt-TKV
Or TKV
<6 >6
Eligible for treatment 
if eGFR 30–89*
Mayo class 1C–E
Or TKV >750 ml
Mayo class 1A–B
Or TKV <750 ml
Eligible for treatment 
if eGFR 30–89*
Repeat MR 
every 3-5 years
Repeat US 
every 2-3 years
Eligible for treatment
Abbreviations: CT – computed tomography; ESRD – end-stage renal disease; FH = family history; 
GFR = glomerular filtration rate; Ht = height-adjusted; MKL = mean kidney length; MR = magnetic resonance; 
TKV = total kidney length; US = ultrasound 
Renal Association Working Group on Tolvaptan in ADPKD, 2016
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Figure 4. A recommended multidisciplinary stepped pathway for managing patients with autosomal dominant polycystic kidney 
disease. For simplicity, this has been drawn as a linear follow-up pathway with the major emphasis being on diagnosis, prognosis and 
treatment at sequential visits. A shared care model with primary care physicians after full evaluation is complete and no treatment planned is 
an option in nationally funded systems. eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; US, ultrasound.
Many patients (though not all) will wish to be assessed for their eli-
gibility for drug treatment or enrolment in clinical trials. Guidelines 
for managing patients are being developed in different countries40–42.
Conclusions
The management of ADPKD, once considered an untreatable dis-
ease, is undergoing a major paradigm shift with more accurate 
diagnostics, prognostic scoring, and availability of new disease-
modifying drugs. This in turn is stimulating a reshaping of patient 
pathways and the reorganisation of clinical services. A continued 
focus on developing new therapeutics and renewed attention to 
patient-centred research priorities are likely to alter the long-term 
management of ADPKD for patients and their families.
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